Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation November 2023 Carol Jamieson, Carla M. Canuso, Dawn F. Ionescu et al.
To assess the effect of esketamine nasal spray on patient-reported outcomes (PROs) in patients with major depressive disorder having active suicidal ideation with intent (MDSI). Patient-level data from two phase 3 studies (ASPIRE I; ASPIRE II) of esketamine + standard of care (SOC) in patients (aged 18-64 years) with MDSI, were pooled. PROs were evaluated from baseline through end of the...
DOI: 10.1007/s11136-023-03451-9 (opens in new tab)
Full text (opens in new tab)
Esketamine
Major depressive disorder
Patient-reported outcomes
Pooled analysis
+1